Peptides and Longevity Research
2026 Review

Peptide-based longevity research continues to accelerate, driven by advances in incretin pharmacology, NAD+ biology, and regenerative compounds. This annual review surveys key developments relevant to laboratory researchers.

1. Triple Incretin Agonists Reach Phase 3

The major story in metabolic peptide research for 2025–2026 is the clinical validation of triple agonism. Retatrutide's TRIUMPH-2 data showing 24.2% weight reduction at 48 weeks validates the triple GIP/GLP-1/glucagon approach, while multiple next-generation compounds (Eli Lilly's orforglipron oral, Novo Nordisk's amycretin) advance through clinical development. The implications for longevity research are significant — metabolic health is the single largest modifiable factor in human healthspan.

2. NAD+ Research: From Mechanism to Tissue Specificity

The NAD+ field has moved beyond simple supplementation studies toward understanding tissue-specific NAD+ metabolism. Recent publications have characterised CD38 as the dominant NADase in aging tissues, developed tissue-specific NMNAT knockout models, and identified extracellular NAD+ signalling through P2RY11 as a regulator of immune function. The field is converging on the understanding that NAD+ biology is highly compartmentalised and tissue-specific — a single precursor may not serve all tissue compartments equally.

3. BPC-157 Research Expands into New Domains

BPC-157 continues to generate novel research applications. 2025 publications have explored BPC-157 in peripheral nerve regeneration (sciatic nerve crush models), cardiac ischaemia-reperfusion injury, and inflammatory bowel disease models. The FAK-mediated mechanism is now well-characterised, and researchers are increasingly exploring dose-response relationships and administration timing — moving beyond proof-of-concept studies toward protocol optimisation.

4. Neuropeptide Research: Semax and Selank Expand

Both Semax and Selank have seen expanded research interest outside their domestic Russian markets. International groups have begun investigating Semax's BDNF-mediated neuroprotection in non-ischaemic models (TBI, neuroinflammation), while Selank's unique non-sedating anxiolytic profile has attracted interest from psychiatric research groups studying stress-induced behavioural models.

5. Regenerative Peptides: TB-500 and GHK-Cu

TB-500 (Thymosin Beta-4) research continues to develop its cardiac protection application, with several groups exploring PKCε-Akt pathway activation in myocardial ischaemia models. GHK-Cu research has expanded into bone regeneration, with publications demonstrating accelerated callus formation and mineralisation in fracture models — applications beyond its well-characterised dermal effects.

6. Quality Standards and Reproducibility

A growing theme in the 2025–2026 peptide literature is emphasis on analytical quality standards. Multiple editorial groups have called for mandatory COA publication as a precondition for peptide research publication. Third-party HPLC and MS verification are increasingly expected by reviewers, particularly for studies involving novel or high-impact findings. Researchers should verify COA data for every batch — batch-to-batch variability in less scrupulous supply chains can compromise multi-year research programmes.

Emerging Research Directions to Watch

• Combination peptide protocols: Sequential or staggered multi-peptide protocols for comprehensive tissue repair research.
• Oral incretin development: Small molecule GLP-1 agonists (orforglipron) and non-injectable peptide delivery systems.
• Mitochondrial-targeted peptides: Compounds specifically designed to address mitochondrial dysfunction in aging.
• Sex-dependent peptide responses: Growing recognition that peptide pharmacology differs between male and female research models.

---